1-20 of 25
Garth Powis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Modeling of Patient-Derived Xenografts in Colorectal Cancer

Anastasia Katsiampoura, Kanwal Raghav, Zhi-Qin Jiang, David G. Menter, Andreas Varkaris, Maria P. Morelli, Shanequa Manuel, Ji Wu, Alexey V. Sorokin, Bahar Salimian Rizi, Christopher Bristow, Feng Tian, Susan Airhart, Mingshan Cheng, Bradley M. Broom, Jeffrey Morris, Michael J. Overman, Garth Powis, Scott Kopetz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1435–1442.
https://doi.org/10.1158/1535-7163.MCT-16-0721
Published: 04 July 2017
View articletitled, Modeling of Patient-Derived Xenografts in Colorectal Cancer
Open the PDF for Modeling of Patient-Derived Xenografts in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C131: ‘KRAS addiction’ an artifact of 2D culture? Inhibitors of the mut-KRAS NSCLC 3D growth

D. Lynn Kirkpatrick, Roisin Delaney, Geoff Grandjean, Assael Madrigal, Martin Indarte, Mike Scott, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C131.
https://doi.org/10.1158/1535-7163.TARG-15-C131
Published: 01 December 2015
View articletitled, Abstract C131: ‘KRAS addiction’ an artifact of 2D culture? Inhibitors of the mut-KRAS NSCLC 3D growth
Journal Articles

The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression

Jeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, Eun Jeong Yu, Tae Soo Kim, You Keun Shin, Xianglan Zhang, Kyu Hyun Park, Seung Woo Park, Hyun Cheol Chung, Garth Powis
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (12): 3074–3085.
https://doi.org/10.1158/1535-7163.MCT-13-1001
Published: 04 December 2014
View articletitled, The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Open the PDF for The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression in another window
Includes: Supplementary data
Journal Articles

Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation.

Hei-Cheul Jeung, Galina Kiriakova, Lynn Kirkpatrick, Martin Indarte, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A199.
https://doi.org/10.1158/1535-7163.TARG-11-A199
Published: 12 November 2011
View articletitled, Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation.
Journal Articles

Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer.

Emmanuelle Meuillet, Sylvester Moses, Jenny Johnson, Robert Lemos, Mena F. Abdelmelek, Garth Powis, Lynn Kirkpatrick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A213.
https://doi.org/10.1158/1535-7163.TARG-11-A213
Published: 12 November 2011
View articletitled, Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer.
Journal Articles

Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling.

Nathan T. Ihle, Geoff Grandjean, John Kingston, Shuxing Zhang, Lei Du-Curry, Martin Indarte, Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A197.
https://doi.org/10.1158/1535-7163.TARG-11-A197
Published: 12 November 2011
View articletitled, Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling.
Journal Articles

Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer

David L. Schwartz, James A. Bankson, Robert Lemos, Jr., Stephen Y. Lai, Arun K. Thittai, Yi He, Galen Hostetter, Michael J. Demeure, Daniel D. Von Hoff, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 2057–2067.
https://doi.org/10.1158/1535-7163.MCT-09-0768
Published: 07 July 2010
View articletitled, Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer
Open the PDF for Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer in another window
Journal Articles

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Emmanuelle J. Meuillet, Song Zuohe, Robert Lemos, Nathan Ihle, John Kingston, Ryan Watkins, Sylvestor A. Moses, Shuxing Zhang, Lei Du-Cuny, Roy Herbst, Jörg J. Jacoby, Li Li Zhou, Ali M. Ahad, Eugene A. Mash, D. Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (3): 706–717.
https://doi.org/10.1158/1535-7163.MCT-09-0985
Published: 09 March 2010
View articletitled, Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Open the PDF for Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor in another window
Journal Articles

Abstract B194: Enhanced antitumor activity of the HIF‐1 inhibitor PX‐478 combined with radiation and chemotherapy in pancreatic cancer

Garth Powis, Daniel Von Hoff, James Bankson, Robert Iemos, Galen Hostetter, Michael Demeure, David Schwartz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B194.
https://doi.org/10.1158/1535-7163.TARG-09-B194
Published: 10 December 2009
View articletitled, Abstract B194: Enhanced antitumor activity of the HIF‐1 inhibitor PX‐478 combined with radiation and chemotherapy in pancreatic cancer
Journal Articles

Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor

Garth Powis, Sylvestor A. Moses, Shuxing Zhang, Lei Du‐Cuny, Zuohe Song, Roy Herbst, Joerg Jacoby, Lynn Kirkpatrick, Eugene Mash, Emmanuelle J. Meuillet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B139.
https://doi.org/10.1158/1535-7163.TARG-09-B139
Published: 10 December 2009
View articletitled, Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor
Journal Articles

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

David L. Schwartz, Garth Powis, Arun Thitai-Kumar, Yi He, James Bankson, Ryan Williams, Robert Lemos, Junghwan Oh, Andrei Volgin, Suren Soghomonyan, Ryuichi Nishii, Mian Alauddin, Uday Mukhopadhay, Zhenghong Peng, William Bornmann, Juri Gelovani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (4): 947–958.
https://doi.org/10.1158/1535-7163.MCT-08-0981
Published: 16 April 2009
View articletitled, The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects
Open the PDF for The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects in another window
Journal Articles

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Nathan T. Ihle, Robert Lemos, David Schwartz, Junghwan Oh, Robert J. Halter, Peter Wipf, Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (1): 94–100.
https://doi.org/10.1158/1535-7163.MCT-08-0714
Published: 12 January 2009
View articletitled, Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity
Open the PDF for Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity in another window
Journal Articles

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Nathan T. Ihle, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (1): 1–9.
https://doi.org/10.1158/1535-7163.MCT-08-0801
Published: 12 January 2009
View articletitled, Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
Open the PDF for Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy in another window
Journal Articles

Discovery of a novel class of AKT pleckstrin homology domain inhibitors

Daruka Mahadevan, Garth Powis, Eugene A. Mash, Benjamin George, Vijay M. Gokhale, Shuxing Zhang, Kishore Shakalya, Lei Du-Cuny, Margareta Berggren, M. Ahad Ali, Umasish Jana, Nathan Ihle, Sylvestor Moses, Chloe Franklin, Satya Narayan, Nikhil Shirahatti, Emmanuelle J. Meuillet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 2621–2632.
https://doi.org/10.1158/1535-7163.MCT-07-2276
Published: 11 September 2008
View articletitled, Discovery of a novel class of AKT pleckstrin homology domain inhibitors
Open the PDF for Discovery of a novel class of AKT pleckstrin homology domain inhibitors in another window
Journal Articles

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

Mei Y. Koh, Taly Spivak-Kroizman, Sara Venturini, Sarah Welsh, Ryan R. Williams, D. Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (1): 90–100.
https://doi.org/10.1158/1535-7163.MCT-07-0463
Published: 17 January 2008
View articletitled, Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α
Open the PDF for Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α in another window
Journal Articles

The molecular mechanisms for the activity of PX-478, an antitumor inhibitor of hypoxia-inducible factor 1Ά

Mei Yee Koh, Taly Spivak-Kroizman, Sara Venturini, Sarah Welsh, Ryan Williams, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A284.
Published: 01 November 2007
View articletitled, The molecular mechanisms for the activity of PX-478, an antitumor inhibitor of hypoxia-inducible factor 1Ά
Journal Articles

Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models.

Nathan Ihle, Robert Lemos, Gordon Mills, Paul Dent, Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A257.
Published: 01 November 2007
View articletitled, Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models.
Journal Articles

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

Amy L. Howes, Gary G. Chiang, Elizabeth S. Lang, Caroline B. Ho, Garth Powis, Kristiina Vuori, Robert T. Abraham
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (9): 2505–2514.
https://doi.org/10.1158/1535-7163.MCT-06-0698
Published: 17 September 2007
View articletitled, The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
Open the PDF for The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures in another window
Journal Articles

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

Garth Powis, Peter Wipf, Stephen M. Lynch, Anne Birmingham, D. Lynn Kirkpatrick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 630–636.
https://doi.org/10.1158/1535-7163.MCT-05-0487
Published: 16 March 2006
View articletitled, Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase
Open the PDF for Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase in another window
Journal Articles

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Nathan T. Ihle, Gillian Paine-Murrieta, Margareta I. Berggren, Amanda Baker, Wendy R. Tate, Peter Wipf, Robert T. Abraham, D. Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (9): 1349–1357.
https://doi.org/10.1158/1535-7163.MCT-05-0149
Published: 16 September 2005
View articletitled, The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts
Open the PDF for The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts in another window